ACADIA Pharmaceuticals Inc. (ACAD)
Largest Insider Buys in Sector
ACAD Stock Price History Chart
ACAD Stock Performance
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 …
Insider Activity of ACADIA Pharmaceuticals Inc.
Over the last 12 months, insiders at ACADIA Pharmaceuticals Inc. have bought $0 and sold $2.9M worth of ACADIA Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at ACADIA Pharmaceuticals Inc. have bought $31.9M and sold $12.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 294,154 shares for transaction amount of $7.45M was made by BAKER BROS. ADVISORS LP () on 2023‑05‑24.
List of Insider Buy and Sell Transactions, ACADIA Pharmaceuticals Inc.
| 2024-08-19 | Sale | CEO | 31,747 0.0186% | $15.28 | $485,094 | -0.82% | ||
| 2024-08-19 | Sale | EVP, COO, HEAD OF COMMERCIAL | 9,534 0.0056% | $15.28 | $145,680 | -0.82% | ||
| 2024-08-19 | Sale | EVP, CHIEF FINANCIAL OFFICER | 9,733 0.0057% | $15.28 | $148,720 | -0.82% | ||
| 2024-06-10 | Sale | EVP, CHIEF FINANCIAL OFFICER | 975 0.0006% | $14.79 | $14,420 | +5.38% | ||
| 2024-05-02 | Sale | CEO | 11,427 0.0069% | $16.94 | $193,573 | -9.90% | ||
| 2024-05-02 | Sale | EVP, COO, HEAD OF COMMERCIAL | 3,477 0.0021% | $16.94 | $58,900 | -9.90% | ||
| 2024-05-02 | Sale | EVP, CHIEF FINANCIAL OFFICER | 3,503 0.0021% | $16.94 | $59,341 | -9.90% | ||
| 2024-05-02 | Sale | PRINCIPAL ACCOUNTING OFFICER | 1,326 0.0008% | $16.94 | $22,462 | -9.90% | ||
| 2024-04-08 | Sale | CEO | 26,574 0.0162% | $17.87 | $474,877 | -11.85% | ||
| 2024-04-08 | Sale | EVP, COO, HEAD OF COMMERCIAL | 2,568 0.0016% | $17.87 | $45,890 | -11.85% | ||
| 2024-04-08 | Sale | EVP, CHIEF FINANCIAL OFFICER | 2,716 0.0017% | $17.87 | $48,535 | -11.85% | ||
| 2024-04-08 | Sale | PRINCIPAL ACCOUNTING OFFICER | 1,790 0.0011% | $17.87 | $31,987 | -11.85% | ||
| 2024-03-27 | Sale | CEO | 17,714 0.0106% | $17.90 | $317,081 | -13.43% | ||
| 2024-03-27 | Sale | EVP, COO, HEAD OF COMMERCIAL | 5,140 0.0031% | $17.90 | $92,006 | -13.43% | ||
| 2024-03-27 | Sale | EVP, CHIEF FINANCIAL OFFICER | 5,434 0.0032% | $17.90 | $97,269 | -13.43% | ||
| 2024-02-26 | Sale | CEO | 5,577 0.0032% | $24.67 | $137,585 | -37.30% | ||
| 2024-02-26 | Sale | EVP, COO, HEAD OF COMMERCIAL | 624 0.0004% | $24.67 | $15,394 | -37.30% | ||
| 2024-02-26 | Sale | EVP, CHIEF FINANCIAL OFFICER | 772 0.0004% | $24.67 | $19,045 | -37.30% | ||
| 2024-02-26 | Sale | PRINCIPAL ACCOUNTING OFFICER | 474 0.0003% | $24.67 | $11,694 | -37.30% | ||
| 2024-01-08 | Sale | CEO | 3,732 0.0023% | $29.96 | $111,811 | -43.92% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 39058564 23.5468% | $15.74 | 16 | 0 | +14.48% | |
| 14159, L.P. | 20278008 12.2248% | $15.74 | 1 | 0 | +3.15% | |
| BAKER FELIX | 18001203 10.8522% | $15.74 | 4 | 0 | +58.48% | |
| OXFORD BIOSCIENCE PARTNERS IV LP | 10 percent owner | 3160238 1.9052% | $15.74 | 2 | 0 | +29.7% |
| WALTON ALAN G | 2573836 1.5517% | $15.74 | 1 | 0 | +11.11% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $792.57M | 25.94 | 42.86M | 0% | +$0 | 5.69 | |
| RTW Investments, LP | $255.7M | 8.37 | 13.83M | +22.89% | +$47.63M | 3.83 | |
| The Vanguard Group | $245.89M | 8.05 | 13.3M | -0.73% | -$1.8M | 0.01 | |
| BlackRock | $215.76M | 7.06 | 11.67M | +2.26% | +$4.78M | 0.01 | |
| State Street | $110.97M | 3.63 | 6M | -7.17% | -$8.57M | 0.01 |